In metastatic urothelial carcinoma, mutations in the ARID1A gene and increased expression of C‐X‐C motif chemokine ligand 13 (CXCL13) in cancer tissue improve sensitivity to immune checkpoint therapy; both can serve as biomarkers predicting efficacy of such therapy [54]. Here, ARID1A is linked to cancer.